The Leukemia & Lymphoma Society® and Shape Pharmaceuticals Partner to Advance Clinical Development of Novel, Topical Therapy for Cutaneous T-Cell Lymphoma
WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July 27 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Shape Pharmaceuticals announced today that they have entered into a partnership to advance Shape's novel, topical treatment for cutaneous T-Cell lymphoma (CTCL) into clinical development. The compound, SHP-141, is a...
June 17 (Reuters) - Allos Therapeutics Inc (ALTH.O) said its experimental cancer drug for cutaneous T-cell lymphoma (CTCL) received an orphan drug status from the European health regulators.
The designation from the European Commission may provide Allos up to 10-year market exclusivity in Europe, upon marketing approval of the drug pralatrexate.
Pralatrexate Demonstrates High Activity in Patients With Relapsed or Refractory Cutaneous-T-Cell Lymphoma: Presented at EHA
Doctor's Guide
DGDispatch
By Jenny Powers
BARCELONA, Spain -- June 15, 2010 -- Patients with cutaneous-T-cell lymphoma (CTCL) who failed prior systemic therapy responded to pralatrexate without experiencing significant toxicity, according to a study presented here at the 15th Congress of the European Hematology Association (EHA). ...
June 11, 2010 11:45 AM Eastern Daylight Time
Allos Therapeutics’ FOLOTYN Shows Activity and Tolerability in Phase 1 Dose Finding Study in Patients with Relapsed or Refractory CTCL
–New Data Presented at 15th Annual EHA Meeting Demonstrates Responses to FOLOTYN in Patients Failing Prior Systemic Therapies–
BARCELONA, Spain & WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced updated data from its ongoing dose finding...
Allos Therapeutics Announces FOLOTYN® Data Presentations at the American Society of Clinical Oncology and the Congress of the European Hematology Association
2010 American Society of Clinical Oncology Annual Meeting
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that data on FOLOTYN® (pralatrexate injection) will be presented at two upcoming medical conferences:...
